American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1381)
  9. Gastrointestinal Oncology Service (1356)
  10. Hematologic Malignancies, Division of (1286)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2591)
  3. Editorial (79)
  4. Review (70)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6408)
  2. Solid Tumor Oncology Division (5546)
  3. Survivorship Research (1999)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (308)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (303)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8712)
  2. JCO Precision Oncology (174)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (54)
  6. JCO Oncology Practice (12)

More Publications

Results (9195)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer
    Meeting Abstract

    Mai, N.; Liu, B.; Safonov, A.; Shen, S.; Zelizer, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.; Modi, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial
    Meeting Abstract

    Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations
    Meeting Abstract

    Teysir, J.; Shen, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer
    Meeting Abstract

    Ah-Reum An, J.; Jasper, J.; Cabel, L.; Yildirim, S. Y.; da Silva, E. M.; Patel, R. K.; LaBella, M.; Teysir, J.; Mai, N.; Safonov, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
    Meeting Abstract

    Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, É.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
    Meeting Abstract

    Oliveira, M.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; Krop, I. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer
    Meeting Abstract

    Iglesias, M. J. M.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Doud, R. P.; Gallagher, G. B.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Obesity, chemotherapy dosing, and toxicity: Results from the Optimal Breast Cancer Chemotherapy Dosing study
    Meeting Abstract

    Kantor, E.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Doud, R. P.; Gallagher, G. B.; Griggs, J. J.; Monroy-Iglesias, M. J.; Kolevska, T.; Kroenke, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
    Meeting Abstract

    Fanucci, K.; Dueck, A. C.; Mayer, E. L.; Martin, M.; Haddad, T. C.; Zdenkowski, N.; Steger, G. G.; Novik, Y.; Suga, J. M.; Lemieux, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save